EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Targeting p21 ‐High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Na Ta, Shuyi Wang, Boyan Zhang, Ning Liu, Yingchen Han, Aoran Liu iD, Ying Xu, Tingsong Chen iD, Ye Zhang, Qiuhua Luo iD, Tao Han iD

Advanced Science · 2026

DOI: 10.1002/advs.76384 ↗

At a glance

Journal article in Advanced Science, 2026. Written by Na Ta and 10 co-authors. Institution: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, P. R. China. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Portal Vein, Kupffer Cells. 49 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Educational funding of Liaoning Province, Liaoning Provincial Science and Technology Plan Projects.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) are associated with a significantly poor prognosis and limited treatment options. Single‐cell RNA sequencing (scRNA‐seq) has revealed senescent Kupffer cells (sKCs), which are characterized by high levels of p21 expression and enriched in the tumor microenvironment (TME) of HCC‐PVTT. These sKCs exhibit a pronounced senescence‐associated secretory phenotype (SASP), promoting the proliferation and invasion of tumors and crosstalk with cancer‐associated fibroblasts. To target sKCs, a biomimetic nanodelivery system termed SKEV@AAV has been developed. This system comprises adeno‐associated virus (AAV) vectors carrying p21 ‐specific shRNA, encapsulated within sKCs‐derived exosomes (SKEV). SKEV@AAV effectively downregulated p21 , suppressed SASP signaling, and disrupted pro‐tumor interactions between sKCs and cancer‐associated fibroblasts. In an orthotopic PVTT model, SKEV@AAV showed single‐agent antitumor activity and attenuated SASP‐associated inflammatory remodeling. Furthermore, the combination efficacy with anti‐PD‐1 was evaluated in a murine splenic liver‐metastasis model, where SKEV@AAV reduced tumor burden, enhanced CD8 + T‐cell infiltration, decreased regulatory T cells, and promoted memory T‐cell differentiation. Our findings reveal a pivotal role of sKCs in mediating immune suppression in HCC‐PVTT and provide a nanotherapeutic strategy that reverses sKCs' senescence, reprograms the TME, and ultimately enhances antitumor immune activation.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPortal VeinKupffer CellsCyclin-Dependent Kinase Inhibitor p21Venous ThrombosisAnimalsHumansMiceTumor MicroenvironmentCellular SenescenceMale

Author keywords

combination immunotherapyexosome‐based deliveryhepatocellular carcinomap21portal vein tumor thrombussenescent Kupffer cellstumor microenvironment

Substances

Cyclin-Dependent Kinase Inhibitor p21

Authors and institutions

  • Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, P. R. China.
  • Department of Neurology, The Second Affiliated Hospital of Dalian Medical University, Dalian, P. R. China.
  • Department of Pharmacy, The First Hospital of China Medical University, Shenyang, Liaoning, P. R. China.
  • Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, P. R. China.
  • The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, Liaoning, P. R. China.
  • School of Medicine, Southern University of Science and Technology, Shenzhen, P. R. China.

ORCID profiles: Aoran Liu, Tingsong Chen, Qiuhua Luo, Tao Han

Funding

  • National Natural Science Foundation of China
  • Educational funding of Liaoning Province
  • Liaoning Provincial Science and Technology Plan Projects
  • Shenyang Young and Middle-aged Science and Technology Innovation Talent Support Program
  • Shenyang Science and Technology Plan Projects
  • New Quality Clinical Specialty Program of High-end Medical Disciplinary Construction in Shanghai Pudong New Area
  • Key Discipline Program of the Shanghai Pudong New Area Health Commission
  • Liaoning Provincial Department of Science and Technology Joint Project

Cite

APA

Ta, N., Wang, S., Zhang, B., Liu, N., Han, Y., Liu, A., Xu, Y., Chen, T., Zhang, Y., Luo, Q., & Han, T. (2026). Targeting p21 ‐High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Advanced Science. https://doi.org/10.1002/advs.76384

Vancouver

Ta N, Wang S, Zhang B, Liu N, Han Y, Liu A, et al. Targeting p21 ‐High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Advanced Science. 2026. doi:10.1002/advs.76384

BibTeX
@article{Ta2026,
  author = {Ta, Na and Wang, Shuyi and Zhang, Boyan and Liu, Ning and Han, Yingchen and Liu, Aoran and Xu, Ying and Chen, Tingsong and Zhang, Ye and Luo, Qiuhua and Han, Tao},
  title = {Targeting p21 ‐High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.76384}
}
Start for free →